<?xml version="1.0" encoding="UTF-8"?>
<p id="Par145">AVATAR is a multicentre phase II registry trial that aims to examine the SRT's role as a treatment option for patients with oligoprogressive ER-positive HER2-negative advanced breast cancer. This study aims to accrue 32 patients and examine the impact of SRT on maximizing the benefit of systemic therapy, overall survival, progression free survival and toxicity.</p>
